Ultimovacs
Menu Close ✕
  • About
    • About Ultimovacs
    • Team
    • Board of directors
  • Technology
    • Technology overview
    • Immunotherapy
    • Clinical studies
  • Investors
    • Shares
    • Reports and presentations
    • Investor relations contacts
    • Analyst coverage
    • Governance
    • News
  • Contact

Enabling the immune system to fight cancer

Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer.

Read more about Ultimovacs

Our mission is to extend and improve the life of patients by directing the immune system against the core of cancer.

We will provide universally accessible solutions.

Tweets | @Ultimovacs

Press Releases

Securities Regulation of 29 June 2007 (“STA”) – Disclosure of Significant Shareholding 20, January, 2021
Financial calendar 20, January, 2021
Ultimovacs ASA: Mandatory notification of trade by primary insider 15, January, 2021
Ultimovacs ASA: Mandatory notification of trade by primary insider 13, January, 2021
Ultimovacs ASA: Mandatory notification of trade by primary insider 12, January, 2021
See all

News

Article in HealthTalkNorge featuring Ultimovacs’ CMO Jens Bjørheim discussing the DOVACC trial, ovarian cancer and Ultimovacs’ development program 27, January, 2021
QuickView company update on Ultimovacs has been published by Edison Investment Research (company sponsored research) 20, January, 2021
Biostock article: Ultimovacs announces collaboration with AstraZeneca 12, January, 2021
HealthTalk Norge with an article about FOCUS, Ultimovacs’ fourth phase II trial 4, January, 2021
BioStock has published the article: “Ultimovacs initiates fourth phase II trial with UV1” 23, December, 2020
Full version of the publication in ‘Frontiers in Immunology’ featuring positive results from Phase I trial evaluating UV1 in Non-Small Cell Lung Cancer is now available 26, November, 2020
See all
E-mail: mail@ultimovacs.com
Phone number: +47 413 80 080
Ullernchausséen 64
0379 Oslo
Norway View in Google Maps

Technology

  • Technology
  • Clinical studies
  • Immunotherapy

Ultimovacs

  • About Ultimovacs
  • Team
  • Board of directors
  • Contact us

Investors

  • Share information
  • Financial reports
  • Investor relations contacts
  • News
Copyright © Ultimovacs ASA 2021